 |
BioWorld-Insight-2011-08-15
Biotech Deal Trends Looking Good, Investors Still Crucial
In Biotech's New Normal, Skills at CEO Level Evolve
The last four years have brought significant CEO turnover in the drug industry. Almost every big pharma has felt the churn, including Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Roche AG, Sanofi SA, Eli Lilly and Co., Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., to name a few.